S&P 500

MRK

Merck & Co., Inc.

latest move

+15.74%

2026-08-25

3 sessions · 2026-08-19 → 2026-08-25 · avg 13.55% · largest 15.74%

Merck & Co., Inc. is a global pharmaceutical research company specializing in human health therapies, vaccines, and animal health products.

stitched from the price window carried by each report

newest first

+15.74%weekly change

Merck and Moderna announced positive Phase 3 trial results for an individualized mRNA cancer vaccine combined with KEYTRUDA.

+12.30%weekly change

Merck and Moderna reported positive Phase 3 results for an mRNA cancer vaccine with KEYTRUDA in high-risk melanoma.

+12.60%24 hours change

Merck announced positive Phase 3 trial results for Keytruda combined with Moderna's mRNA cancer vaccine in melanoma patients.